Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03380962 · ClinicalTrials.gov registry record · Phase 1
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
A Phase 1 study of End Stage Renal Disease and Kidney Failure, Chronic, sponsored by Stanley Jordan, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03380962 is a Phase 1 study of End Stage Renal Disease and Kidney Failure, Chronic that is active but no longer recruiting, run by Stanley Jordan, MD. The registered enrollment target is 20 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03380962, a Phase 1 study of End Stage Renal Disease and Kidney Failure, Chronic, is active but no longer recruiting, sponsored by Stanley Jordan, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients who have had a previous allograft failure represent a major problem for transplant centers as they are highly-human leukocyte antigen (HLA) sensitized and unlikely to receive another transplant without significant desensitization. This single center, phase I/II, open label single-arm exploratory study focuses on enrolling twenty patients (ages 15-75) who will begin desensitization therapy to achieve HLA incompatible (HLAi) renal transplantation. Patients who qualify will receive up to 6 doses of clazakizumab 25 mg monthly pre-transplantation. If patients receive an HLAi transplant during the study, the participants will continue to receive another 6 monthly doses of clazakizumab 25 mg, followed by a 6 month protocol biopsy. Patients will continue another 6 doses over 6 months if improvements are seen after the 6th dose of clazakizumab. Patients who develop evidence of persistent allograft dysfunction may have non-protocol biopsies for cause. Patients who receive 12 doses of clazakizumab post-transplant will receive a 12M protocol biopsy.
Conditions Studied
Interventions
- DRUG Clazakizumab
Study Locations (1)
California
- Norko Ammerman - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2025-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03380962
The ClinicalTrials.gov registry entry for NCT03380962 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (98% lower). The listed sponsor is Stanley Jordan, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Clazakizumab is the first listed.
NCT03380962 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03380962 about?
NCT03380962 is a clinical study titled "Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant". Patients who have had a previous allograft failure represent a major problem for transplant centers as they are highly-human leukocyte antigen (HLA) sensitized and unlikely to receive another transplant without significant desensitization. This single center, phase I/II, open label single-arm explor...
What is the current status of trial NCT03380962?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-02-27. Estimated completion is 2025-08-30.
What conditions does trial NCT03380962 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Kidney Failure, Chronic, Kidney Transplant; Complications, Antibody-mediated Rejection, Transplant;Failure,Kidney.
What interventions are being tested in trial NCT03380962?
The interventions under investigation include: Clazakizumab (DRUG).
Who is sponsoring clinical trial NCT03380962?
This trial is sponsored by Stanley Jordan, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03380962 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.